• 13:03

Immunicum publishes promising data for the Company’s CD70-technology for adoptive immunotherapy in a scientific journal. The results indicate a robust method to expand tumor-specific T-cells with improved quality in comparison with established expansion protocols. 

In a publication entitled ”Allogeneic lymphocyte-licensed DCs expand T-cells with improved anti-tumor activity and resistance to oxidative stress and immunosuppressive factors”, published today in the American Journal Molecular Therapy- Methods & Clinical Development  (published by Nature Publishing Group in collaboration with the American Society of Gene & Cell Therapy), Professor Essand’s research group at the Rudbeck Laboratory in Uppsala compared Immunicum’s patent-pending expansion protocol called CD70-CD3 with established expansion protocols.

The article shows that T-cells expanded by Immunicum’s protocols, compared to established protocols, have better viability, better ability to kill tumor cells in the test tube, as well as superior proliferative response during tumor cell killing when the cells are subjected to immunosuppressive factors that reflect the “hostile” tumor environment.

Read the publication here.